CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

Data ReadoutpositivePositive
AI Analysis

Summary

A dual-acting drug developed by AbbVie and Genmab demonstrated positive results in a frontline lymphoma trial. The collaboration between the two companies achieved efficacy in the lymphoma indication.

Clinical Trial Data

Primary Endpoint

Met

Importance:6/10
Sentiment:
0.75
lymphomadual-actingclinical_trialfrontline
Related Companies

Read the original article

Published by yahoo_finance on October 6, 2026 3:42 PM

Read Original